Our in silico models suggest that EZH2 may play an important role in loss of EGF in DCT cells and in increased de novo expression of CCL2, which is associated with the incidence of AKI and CKD, as well as progression of CKD. This evidence concerns the gene CCL2 and chronic kidney disease.